Abbott Laboratories
ABT
$113.61
$0.000.00%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.32% | 142.36% | 151.56% | 139.82% | 134.18% |
| Total Depreciation and Amortization | -3.17% | -2.88% | -3.26% | -2.25% | -0.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.88% | 42.64% | 42.27% | 43.76% | 50.00% |
| Change in Net Operating Assets | 91.29% | -757.56% | -440.68% | -251.35% | -272.40% |
| Cash from Operations | 11.78% | 4.48% | 14.39% | 25.30% | 17.86% |
| Capital Expenditure | 1.63% | 1.78% | -0.71% | -3.29% | -0.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 41.18% | -- | -- |
| Divestitures | -- | -100.00% | -100.00% | -97.50% | -97.50% |
| Other Investing Activities | -10.61% | -60.00% | -450.00% | -133.33% | -40.43% |
| Cash from Investing | -3.59% | -3.44% | -7.53% | 23.03% | 25.38% |
| Total Debt Issued | -97.76% | -98.36% | -97.94% | 873.91% | 869.57% |
| Total Debt Repaid | -113.03% | -95.21% | 38.76% | 35.35% | 69.58% |
| Issuance of Common Stock | 50.00% | 52.38% | 85.23% | 74.48% | 58.08% |
| Repurchase of Common Stock | 31.04% | 26.88% | -175.92% | -47.75% | -5.54% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.30% | -7.38% | -7.55% | -7.78% | -7.87% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -16.75% | -21.05% | -3.62% | 8.37% | 23.79% |
| Foreign Exchange rate Adjustments | 173.96% | -250.00% | 152.83% | 46.27% | -317.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.83% | -105.54% | 95.75% | 108.62% | 124.11% |